NCT03686215View on ClinicalTrials.gov

Investigation of Novel Surgical Imaging for Tumor Excision

PHASE3CompletedINTERVENTIONAL
Enrollment

406

Participants

Timeline

Start Date

November 4, 2019

Primary Completion Date

December 9, 2021

Study Completion Date

May 4, 2022

Conditions
Breast Cancer
Interventions
COMBINATION_PRODUCT

Study Device Arm

LUM015 will be administered 2 to 6 hours prior to surgery. The LUM Imaging device will be used to assist in the removal of additional tumor tissue.

Trial Locations (14)

17033

Penn State Health Milton S. Hershey Medical Center, Hershey

27103

Novant Health Salem Surgical Associates, Winston-Salem

27710

Duke Cancer Center, Durham

32207

Baptist MD Anderson Cancer Center, Jacksonville

33612

Moffitt Cancer Center, Tampa

33756

Morton Plant Mease Health Care Oncology Research, Clearwater

36604

University of South Alabama Mitchell Cancer Institute, Mobile

44195

Cleveland Clinic, Cleveland

48073

Comprehensive Breast Care Center/Beaumont Health, Royal Oak

77030

The University of Texas MD Anderson Cancer Center, Houston

85258

HonorHealth Research Institute, Scottsdale

94304

Stanford Hospital and Clinics, Palo Alto

98405

CHI Franciscan Research Center, Tacoma

02114

Massachusetts General Hospital, Boston

Sponsors

Lead Sponsor

Lumicell, Inc.
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Lumicell, Inc.

INDUSTRY